NASDAQ:MTEM

Molecular Templates Competitors

$8.53
+0.66 (+8.39 %)
(As of 04/14/2021 01:24 PM ET)
Add
Compare
Today's Range
$7.91
Now: $8.53
$8.62
50-Day Range
$7.82
MA: $11.12
$12.70
52-Week Range
$7.51
Now: $8.53
$18.44
Volume22,240 shs
Average Volume451,723 shs
Market Capitalization$478.12 million
P/E RatioN/A
Dividend YieldN/A
Beta2.08

Competitors

Molecular Templates (NASDAQ:MTEM) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying MTEM stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Molecular Templates, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Molecular Templates (NASDAQ:MTEM) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Volatility and Risk

Molecular Templates has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares Molecular Templates and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Molecular Templates-428.65%-111.43%-56.35%
Amgen29.42%95.55%15.52%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Molecular Templates and Amgen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Molecular Templates01202.67
Amgen0101402.58

Molecular Templates currently has a consensus target price of $18.3333, indicating a potential upside of 115.18%. Amgen has a consensus target price of $259.4091, indicating a potential upside of 3.98%. Given Molecular Templates' stronger consensus rating and higher possible upside, analysts plainly believe Molecular Templates is more favorable than Amgen.

Valuation and Earnings

This table compares Molecular Templates and Amgen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular Templates$22.27 million21.47$-69,420,000.00($1.26)-6.77
Amgen$23.36 billion6.15$7.84 billion$14.8216.84

Amgen has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

60.7% of Molecular Templates shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 38.2% of Molecular Templates shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Amgen beats Molecular Templates on 9 of the 14 factors compared between the two stocks.

Molecular Templates (NASDAQ:MTEM) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Volatility and Risk

Molecular Templates has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Profitability

This table compares Molecular Templates and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Molecular Templates-428.65%-111.43%-56.35%
Gilead Sciences5.48%37.77%12.76%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Molecular Templates and Gilead Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Molecular Templates01202.67
Gilead Sciences191302.52

Molecular Templates currently has a consensus target price of $18.3333, indicating a potential upside of 115.18%. Gilead Sciences has a consensus target price of $97.92, indicating a potential upside of 49.72%. Given Molecular Templates' stronger consensus rating and higher possible upside, analysts plainly believe Molecular Templates is more favorable than Gilead Sciences.

Valuation and Earnings

This table compares Molecular Templates and Gilead Sciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular Templates$22.27 million21.47$-69,420,000.00($1.26)-6.77
Gilead Sciences$22.45 billion3.66$5.39 billion$6.1410.64

Gilead Sciences has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

60.7% of Molecular Templates shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 38.2% of Molecular Templates shares are held by company insiders. Comparatively, 0.1% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Gilead Sciences beats Molecular Templates on 9 of the 14 factors compared between the two stocks.

Molecular Templates (NASDAQ:MTEM) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Volatility and Risk

Molecular Templates has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares Molecular Templates and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Molecular Templates-428.65%-111.43%-56.35%
Vertex Pharmaceuticals38.51%28.55%20.68%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Molecular Templates and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Molecular Templates01202.67
Vertex Pharmaceuticals042112.88

Molecular Templates currently has a consensus target price of $18.3333, indicating a potential upside of 115.18%. Vertex Pharmaceuticals has a consensus target price of $293.1250, indicating a potential upside of 34.35%. Given Molecular Templates' higher possible upside, analysts plainly believe Molecular Templates is more favorable than Vertex Pharmaceuticals.

Valuation and Earnings

This table compares Molecular Templates and Vertex Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular Templates$22.27 million21.47$-69,420,000.00($1.26)-6.77
Vertex Pharmaceuticals$4.16 billion13.58$1.18 billion$4.2950.69

Vertex Pharmaceuticals has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

60.7% of Molecular Templates shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 38.2% of Molecular Templates shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats Molecular Templates on 11 of the 15 factors compared between the two stocks.

Molecular Templates (NASDAQ:MTEM) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Volatility and Risk

Molecular Templates has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500.

Profitability

This table compares Molecular Templates and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Molecular Templates-428.65%-111.43%-56.35%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Molecular Templates and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Molecular Templates01202.67
Regeneron Pharmaceuticals051412.80

Molecular Templates currently has a consensus target price of $18.3333, indicating a potential upside of 115.18%. Regeneron Pharmaceuticals has a consensus target price of $637.2083, indicating a potential upside of 32.49%. Given Molecular Templates' higher possible upside, analysts plainly believe Molecular Templates is more favorable than Regeneron Pharmaceuticals.

Valuation and Earnings

This table compares Molecular Templates and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular Templates$22.27 million21.47$-69,420,000.00($1.26)-6.77
Regeneron Pharmaceuticals$7.86 billion6.54$2.12 billion$21.4722.35

Regeneron Pharmaceuticals has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

60.7% of Molecular Templates shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 38.2% of Molecular Templates shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats Molecular Templates on 11 of the 15 factors compared between the two stocks.

Molecular Templates (NASDAQ:MTEM) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Valuation and Earnings

This table compares Molecular Templates and Biogen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular Templates$22.27 million21.47$-69,420,000.00($1.26)-6.77
Biogen$14.38 billion2.83$5.89 billion$33.577.94

Biogen has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Molecular Templates has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Insider and Institutional Ownership

60.7% of Molecular Templates shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 38.2% of Molecular Templates shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Molecular Templates and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Molecular Templates-428.65%-111.43%-56.35%
Biogen35.63%51.00%23.54%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Molecular Templates and Biogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Molecular Templates01202.67
Biogen5141202.23

Molecular Templates currently has a consensus target price of $18.3333, indicating a potential upside of 115.18%. Biogen has a consensus target price of $303.5862, indicating a potential upside of 13.72%. Given Molecular Templates' stronger consensus rating and higher possible upside, analysts plainly believe Molecular Templates is more favorable than Biogen.

Summary

Biogen beats Molecular Templates on 9 of the 14 factors compared between the two stocks.

Molecular Templates (NASDAQ:MTEM) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares Molecular Templates and Alexion Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular Templates$22.27 million21.47$-69,420,000.00($1.26)-6.77
Alexion Pharmaceuticals$4.99 billion6.85$2.40 billion$9.7415.97

Alexion Pharmaceuticals has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Molecular Templates has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Insider & Institutional Ownership

60.7% of Molecular Templates shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 38.2% of Molecular Templates shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Molecular Templates and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Molecular Templates-428.65%-111.43%-56.35%
Alexion Pharmaceuticals16.32%23.16%14.76%

Analyst Ratings

This is a breakdown of recent recommendations for Molecular Templates and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Molecular Templates01202.67
Alexion Pharmaceuticals017512.30

Molecular Templates currently has a consensus target price of $18.3333, indicating a potential upside of 115.18%. Alexion Pharmaceuticals has a consensus target price of $153.8636, indicating a potential downside of 1.11%. Given Molecular Templates' stronger consensus rating and higher possible upside, equities research analysts plainly believe Molecular Templates is more favorable than Alexion Pharmaceuticals.

Summary

Alexion Pharmaceuticals beats Molecular Templates on 10 of the 15 factors compared between the two stocks.


Molecular Templates Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$249.50+0.2%$143.92 billion$23.36 billion20.12
Gilead Sciences logo
GILD
Gilead Sciences
2.8$65.31+0.6%$81.70 billion$22.45 billion67.33
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$217.45+0.7%$56.14 billion$4.16 billion27.46Analyst Report
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$479.90+0.6%$51.11 billion$7.86 billion17.54Analyst Report
Biogen logo
BIIB
Biogen
1.9$266.66+0.2%$40.55 billion$14.38 billion8.83Analyst Report
Analyst Revision
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$155.57+1.2%$33.80 billion$4.99 billion36.35
Seagen logo
SGEN
Seagen
1.7$145.93+3.5%$25.54 billion$916.71 million57.45Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$130.04+1.6%$21.64 billion$876.29 million-58.84Unusual Options Activity
Incyte logo
INCY
Incyte
1.7$82.40+2.1%$17.73 billion$2.16 billion-52.48
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.98+2.0%$15.98 billion$219.75 million-17.75
Novavax logo
NVAX
Novavax
1.4$203.53+4.4%$14.38 billion$18.66 million-38.99News Coverage
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$78.24+0.6%$14.14 billion$1.70 billion17.90
Repligen logo
RGEN
Repligen
1.5$208.50+2.1%$11.66 billion$270.24 million254.27Analyst Report
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$200.25+0.5%$8.88 billion$1.45 billion18.95Analyst Report
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$95.44+2.6%$8.73 billion$788.10 million102.62Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
Gap Down
Exelixis logo
EXEL
Exelixis
1.9$24.11+2.9%$7.31 billion$967.78 million50.23
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.49+4.3%$6.37 billion$195.99 million290.56
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.21+2.7%$5.79 billion$1.12 billion87.94
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$68.23+2.7%$4.01 billion$806.43 million-9.66Analyst Report
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$74.55+2.4%$3.88 billion$1.11 billion23.97Analyst Report
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$48.52+2.8%$3.29 billion$36.13 million-72.42Unusual Options Activity
Gap Down
Alkermes logo
ALKS
Alkermes
1.2$19.46+3.1%$3.00 billion$1.17 billion-42.30
OPKO Health logo
OPK
OPKO Health
1.9$4.25+2.8%$2.77 billion$901.90 million-23.61
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.10+7.8%$2.46 billion$182.24 million-8.78Analyst Upgrade
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$152.27+3.5%$2.44 billion$120.28 million-153.81Analyst Report
Decrease in Short Interest
News Coverage
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$28.36+0.2%$2.13 billion$638.60 million-10.91
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$121.58+4.9%$1.85 billionN/A-10.98
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$10.37+6.6%$1.72 billion$48.83 million-13.64News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.58+2.6%$1.66 billion$428.41 million15.33News Coverage
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.82+4.6%$1.62 billion$102.43 million-19.70
Codexis logo
CDXS
Codexis
1.1$25.01+3.2%$1.56 billion$68.46 million-71.46Analyst Report
Analyst Revision
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.64+4.8%$1.45 billion$82.27 million-18.63News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.68+0.4%$1.18 billion$261.02 million5.96
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.39+4.1%$1.13 billion$35.22 million-7.58
MannKind logo
MNKD
MannKind
1.4$4.45+5.4%$1.05 billion$63.04 million-21.19Increase in Short Interest
Curis logo
CRIS
Curis
1.1$11.99+5.2%$1.04 billion$10 million-14.62Increase in Short Interest
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.60+1.7%$895.14 million$227.19 million46.11
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$22.29+3.7%$850.53 million$3.57 million-10.00Analyst Upgrade
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$22.91+4.1%$798.13 millionN/A0.00Analyst Report
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.32+2.3%$750.64 million$322.07 million-5.07Decrease in Short Interest
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.52+4.0%$727.39 million$150,000.00-5.03
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$21.64+2.2%$698.95 million$252 million-2.21News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.32+2.8%$641.81 million$143.01 million-1.21
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.73+3.2%$614.14 million$59.29 million-24.87Increase in Short Interest
News Coverage
Gap Up
Agenus logo
AGEN
Agenus
1.6$2.71+0.0%$554.70 million$150.05 million-2.49News Coverage
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$4.24+16.3%$467.89 million$36.63 million-4.99News Coverage
Gap Up
Verastem logo
VSTM
Verastem
1.3$2.68+0.7%$463.50 million$17.46 million-1.90Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.03+2.3%$455.80 million$109.33 million-2.23Analyst Report
Gap Down
Geron logo
GERN
Geron
1.4$1.52+5.9%$455.50 million$460,000.00-4.34Decrease in Short Interest
News Coverage
Gap Down
XOMA logo
XOMA
XOMA
1.3$37.87+0.9%$422.33 million$18.37 million-34.12Increase in Short Interest
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.